In last trading session, VistaGen Therapeutics Inc. (NASDAQ:VTGN) saw 5.11 million shares changing hands with its beta currently measuring 0.43. Company’s recent per share price level of $0.16 trading at -$0.01 or -5.22% at ring of the bell on the day assigns it a market valuation of $33.94M. That closing price of VTGN’s stock is at a discount of -1762.5% from its 52-week high price of $2.98 and is indicating a premium of 12.5% from its 52-week low price of $0.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 15.59 million shares which gives us an average trading volume of 14.82 million if we extend that period to 3-months.
VistaGen Therapeutics Inc. (NASDAQ:VTGN) trade information
Upright in the red during last session for losing -5.22%, in the last five days VTGN remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $0.16 price level, adding 20.79% to its value on the day. VistaGen Therapeutics Inc.’s shares saw a change of -91.63% in year-to-date performance and have moved -13.83% in past 5-day. VistaGen Therapeutics Inc. (NASDAQ:VTGN) showed a performance of -12.20% in past 30-days. Number of shares sold short was 16.77 million shares which calculate 12.17 days to cover the short interests.
VistaGen Therapeutics Inc. (VTGN) estimates and forecasts
Statistics highlight that VistaGen Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -85.92% of value to its shares in past 6 months, showing an annual growth rate of -8.00% while that of industry is 1.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. This year revenue growth is estimated to fall -25.20% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $360k for the same. And 3 analysts are in estimates of company making revenue of $360k in the next quarter that will end on Sep 2022.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 30.70% during past 5 years.
VistaGen Therapeutics Inc. is more likely to be releasing its next quarterly report between February 09 and February 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
VistaGen Therapeutics Inc. (NASDAQ:VTGN)’s Major holders
Insiders are in possession of 0.36% of company’s total shares while institution are holding 73.17 percent of that, with stock having share float percentage of 73.43%. Investors also watch the number of corporate investors in a company very closely, which is 73.17% institutions for VistaGen Therapeutics Inc. that are currently holding shares of the company. NEA Management Company, LLC is the top institutional holder at VTGN for having 16.3 million shares of worth $20.22 million. And as of Mar 30, 2022, it was holding 7.89% of the company’s outstanding shares.
The second largest institutional holder is VR Adviser, LLC, which was holding about 16.05 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 7.77% of outstanding shares, having a total worth of $19.9 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 30, 2022, the former fund manager was holding 5.51 million shares of worth $6.83 million or 2.66% of the total outstanding shares. The later fund manager was in possession of 4.39 million shares on Jun 29, 2022, making its stake of worth around $3.87 million in the company or a holder of 2.13% of company’s stock.